Hanna Lubbos
Endocrinology, Diabetes & Metabolism · Leesville, LANPI 1447262639
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations.
Across 285 payments — averaging $15.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$961
- Dexcom, Inc.$430
- Lilly USA, LLC$408
- Corcept Therapeutics$387
- Amgen$364
- AbbVie$318
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,428100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 74 | $961 |
| Dexcom, Inc. | 31 | $430 |
| Lilly USA, LLC | 30 | $408 |
| Corcept Therapeutics | 19 | $387 |
| Amgen(2 entities) | 22 | $364 |
| AbbVie | 20 | $318 |
| Insulet Corporation | 14 | $309 |
| Bayer | 13 | $230 |
| Sanofi-aventis U.S. LLC | 7 | $114 |
| Medtronic | 3 | $97 |
| AstraZeneca | 6 | $91 |
| Abbott | 6 | $90 |
| Ascendis Pharma Endocrinology Inc | 5 | $83 |
| Tandem Diabetes Care, Inc. | 5 | $70 |
| Regeneron Healthcare Solutions, Inc. | 3 | $66 |
| Merck | 4 | $61 |
| Astellas Pharma US Inc | 4 | $56 |
| Amryt Pharma Holdings Ltd | 2 | $46 |
| GSK | 3 | $42 |
| Vifor Pharma, Inc. | 2 | $29 |
| Exact Sciences | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $19 |
| Novartis | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Cequr Corporation | 1 | $8 |
How this compares
$4,436 in reported general payments places this provider in the 55th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
See all endocrinology, diabetes & metabolism providers in Louisiana →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 319 | $379,176 |
| JardianceEmpagliflozin | 288 | $254,014 |
| EliquisApixaban | 290 | $117,446 |
| JanuviaSitagliptin Phosphate | 142 | $112,407 |
| Tresiba Flextouch U-200Insulin Degludec | 68 | $109,089 |
| JanumetSitagliptin Phos/Metformin Hcl | 86 | $89,063 |
| LinzessLinaclotide | 92 | $71,076 |
| MounjaroTirzepatide | 76 | $63,478 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 56 | $61,844 |
| XareltoRivaroxaban | 101 | $61,142 |
| MyrbetriqMirabegron | 149 | $58,305 |
| TrulicityDulaglutide | 57 | $55,046 |
| Tresiba Flextouch U-100Insulin Degludec | 81 | $36,893 |
| FarxigaDapagliflozin Propanediol | 26 | $34,589 |
| RexultiBrexpiprazole | 43 | $30,829 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $961 | $384,209351 claims |
| MerckJanuvia, Janumet | $61 | $201,470228 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $408 | $127,582160 claims |
| AbbVieLinzess, Vraylar | $318 | $94,266114 claims |
| Johnson & JohnsonXarelto | $14 | $61,142101 claims |
| Astellas Pharma US IncMyrbetriq | $56 | $58,305149 claims |
| AstraZenecaFarxiga | $91 | $34,58926 claims |
| GSKTrelegy Ellipta | $42 | $19,73425 claims |
| NovartisEntresto | $17 | $18,63227 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 95 endocrinology, diabetes & metabolism providers in Louisiana.
Other endocrinology, diabetes & metabolism in Leesville
- Timothy GilbertBaton Rouge$985K
- Vivian FonsecaNew Orleans$658K
- Abdul KhanHammond$587K
- Marideli ScanlanMarrero$444K
- Justin FontenotLafayette$397K
- Ileana TandronSlidell$205K
- Lane FreyThibodaux$202K
- Laura Kimball RavariBossier City$165K
- Lawrence BlondeNew Orleans$142K
- Harold MillerHammond$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.